Compare BioNano Genomics Inc (BNGO) vs LYFT Inc (LYFT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNano Genomics Inc vs LYFT Inc — how do they compare? BioNano Genomics Inc trades at $1.19 (market cap $13.66M), while LYFT Inc trades at $17.56 (market cap $6.64B). The key difference: LYFT Inc is far larger — about 486.1× BioNano Genomics Inc's market cap, and LYFT Inc is trading nearer its 52-week high, BioNano Genomics Inc nearer its low. Which is the better fit depends on your goals.
| BNGO | LYFT | |
|---|---|---|
Market Cap | $13.66M | $6.64B |
Sector | Health | Industrials |
52-Week High | $4.92 | $24.57 |
52-Week Low | $1.06 | $12.65 |
Enterprise Value | $16.26M | $6.11B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BNGO trades at $1.16 with a bullish technical signal supported by moving averages. The company shows improving financial trends with narrowing losses and consistent earnings beats, though it remains unprofitable with negative margins. Recent news highlights operational progress including debt retirement and scientific publications. Valuation ratios appear attractive with P/S of 0.31 and P/B of 0.36.
The outlook remains speculative given persistent losses, but improving cash flow trends and analyst optimism provide catalysts. Key risks include ongoing negative profitability and competitive pressures in genomics. With 57% analyst buy ratings and bullish technical momentum, the stock offers high-risk growth potential for investors comfortable with biotech volatility.
Lyft trades at $17.26, down 1.15% today, with strong technical momentum showing bullish moving averages but overbought RSI signals. The company demonstrates remarkable fundamental improvement with 2025 revenue reaching $6.32B and net income surging to $2.84B, achieving a 45% profit margin. Recent Q2 2026 results showed revenue growth of 16.1% with record active riders exceeding 30 million, though earnings slightly missed estimates amid higher costs.
Lyft presents a compelling turnaround story with accelerating profitability and market share gains against Uber, supported by expanding robotaxi partnerships and international growth. However, elevated valuation multiples, competitive pressures, and ongoing legal scrutiny create headwinds. With analyst consensus at $19.17 representing 11% upside potential, the stock offers growth exposure but requires monitoring of execution risks and expense management.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →About LYFT Inc
Lyft is the second-largest ride-sharing service provider in the U.S., connecting riders and drivers over the Lyft app. Lyft recently entered the Canadian market in an effort to expand its market outside the U.S. Incorporated in 2013, Lyft offers a variety of rides via private vehicles, including traditional private rides, shared rides, and luxury ones. Besides ride-share, Lyft also has entered the bike- and scooter-share market to bring multimodal transportation options to users.
Read more on LYFT →
